Recurrence of colorectal cancer
|
Park et al. 2001, USA [95]
|
Patients with an increase in carcinoembryonic antigen levels of > 5 ng/ml during follow-up testing after the resection of their primary CRC
|
CT+PET versus CT
|
Public payer (Medicare)/CEA using a model approach (decision tree)
|
ICER (US$/LYG): 16,437
|
Fairb
|
Sloka et al. 2004, Canada [96]
|
65-year-old patient presenting with suspected recurrent CRC
|
CT+PET versus CT
|
Hospital/CEA using a model approach (decision tree)
|
Cost savings: C$1,758a
|
Fairb
|
Staging of head and neck cancer
|
Hollenbeak et al. 2001, USA [97]
|
HNSCC patients with no evidence of lymph node involvement
|
CT+PET versus CT
|
Hospital/CEA/CUA using a model approach (decision tree)
|
ICER (US$/LYG (US$/QALY)): 8,718 (2,505)
|
Fairb
|
Restaging of malignant lymphoma
|
Bradbury et al. 2002, UK [29]
|
HD patients who have achieved a partial or complete response to induction therapy
|
(1) All for surveillance; (2) All for consolidation; (3) CT; (4) PET after positive CT; (5) (CT)+PET
|
Health care system/CUA using a model approach (decision model with two components: decision tree and Markov model)
|
Strategies 4 and 5 were found to be cost-effective, provided WTP exceeds £1000/LYG, and for almost all input values considered, provided WTP exceeds £5000/LYG
|
Goodb
|
Diagnosis of solitary pulmonary nodules
|
Dietlein et al. 2000, Germany [98]
|
62-year-old man with a SPN of up to 3 cm without calcification, specula and enlargement of mediastinal lymph nodes
|
(1) WW; (2) TNB; (3) Exploratory surgery; (4) PET
|
Public insurer/CEA using a model approach (decision tree)
|
Best ICER (€/LYG): 3,218 (4 versus 1); the exploratory surgery strategy was found to be dominated by PET
|
Goodb, c
|
Gambhir et al. 1998, USA [99]
|
64-year-old white man (1.5 packs/day smoker) with a 2.5-cm nodule
|
(1) WW (baseline strategy); (2) Thoracotomy; (3) CT; (4) CT+PET
|
Public payer (Medicare)/CEA using a model approach (decision tree)
|
Best ICER (US$/LYG): 3,266 for CT
|
Goodb, c
|
Gould et al. 2003, USA [100]
|
62-year-old patient with a new, non-calcified pulmonary nodule seen on chest radiograph
|
40 clinically plausible sequences of five diagnostic technologies: CT, PET, TNB, surgery, and WW (baseline strategy)
|
Societal/CUA using a model approach (Markov model)
|
Best ICER (US$/QALY): 10,935 for strategy 7 (CT: if results indeterminate, biopsy; if results benign, WW)/7,625 for strategy 7/6,515 for CT (if results indeterminate, surgery; if results benign, WW)**
|
Goodb
|
Staging of non-small cell lung cancer
|
Bradbury et al. 2002, UK [29]
|
Medically fit for either surgery or non-surgical treatment, 62-year-old patient
|
(1) All for surgery; (2) All for non-surgical treatment; (3) MS; (4) PET after negative MS; (5) PET; (6) MS after negative PET; (7) MS after positive PET (no N0/1 M1 disease)
|
Health care system/CUA using a model approach (decision tree)
|
Best ICER (£/QALY): 58,951 for CT-positive patients (7 versus 3); 10,475 for CT-negative patients (7 versus 1)
|
Goodb
|
Dietlein et al. 2000, Germany [31]
|
62-year-old man with histologically established and assessed as locally resectable NSCLC without distant metastases
|
(1) Conventional staging; (2) PET in patients with normal-sized lymph nodes; (3) PET for all; (4) PET without supplementary MS if positive CT and PET; (5) PET without supplementary MS if positive PET
|
Public insurer/CEA using a model approach (decision tree)
|
Best ICER (€/LYG): 143 (2 versus 1); 15,325 (4 versus 2); 17,438 (5 versus 3)
|
Goodb
|
Dussault et al. 2001, Canada [101]
|
65-year-old male with histologically confirmed NSCLC without mediastinal and distant metastases
|
CT+PET versus CT
|
Health care system/CEA using a model approach (decision tree)
|
ICER (C$/LYG): 4,689
|
Goodb
|
Kosuda et al. 2000, Japan [102]
|
Patient with suspected NSCLC, stage IIIB or less
|
CT+PET versus CT
|
Hospital/CEA using a model approach (decision tree)
|
ICER (¥/LYG): 218,000
|
Goodb, c
|
Scott et al. 1998, USA [30]
|
64-year-old male with NSCLC
|
(1) CT (MS after positive CT); (2) PET after negative CT (MS after positive CT); (3) CT+PET (MS after positive PET); (4) CT+PET (MS after positive CT or positive PET after negative CT)
|
Public payer (Medicare)/CEA using a model approach (decision tree)
|
Best ICER (US$/LYG): 25,286 (2 versus 1)
|
Goodc
|
Sloka et al. 2004, Canada [103]
|
65-year-old patient with suspected NSCLC
|
CT+PET versus CT
|
Health care system/CEA using a model approach (decision tree)
|
Cost-savings: C$1,455a
|
Goodb
|